Database

Startups

Main Industry
Health Care
Main Product/Service
1. Cell Therapy
2. Clinical trial
3. MCRcIR
4. MiSaverR
Founded Year
2011
Unified Business No.
53523105
Status
Active
Number of Employees
0
Total Paid-in Capital
200,544,220 (NT$)
Location of Company
Taiwan , Tainan City
Website
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
HONYA Medical is a cutting-edge stem cell pharmaceutical company dedicated to developing advanced regenerative therapies. Focused on combating cardiovascular diseases and other degenerative conditions, HONYA creates state-of-the-art stem cell products that are ethically sourced and manufactured under strict GTP/GMP standards. Their pioneering technologies enable the cultivation, modification, and use of stem cells to repair and regenerate tissues, offering new hope for patients worldwide. With a mission to redefine health through innovation, HONYA is at the forefront of transforming the future of medicine.



More ↓

Similar Companies

TRUST BIO-SONICS INC.

1. Ultrasound Imaging Agents
2. Ultrasound-Mediated Targeted Delivery

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppressants for autoimmune disease treatment and transplant rejection prevention./Utilizing the FAST CGT platform enhance therapeutic efficacy, durability, and precision of MSC therapies for treating inflammatory and ischemic diseases/Integrating cell therapy R&D and clinical applications through the FAST CGT platform to accelerate the development and commercialization

Acura NanoMedicine Corporation

1. Out-licensing of innovative drug products, including the AN-8 series, a novel therapy designed to reverse cancer drug resistance, and other pharmaceuticals.
2. Utilizing proprietary technology platforms — (1) the HTPVAC drug development platform and (2) three nanomedicine delivery platforms to engage in joint new drug development and licensing partnerships